Home > News > Nanogen Expands Real-Time Portfolio
April 25th, 2006
Nanogen Expands Real-Time Portfolio
Abstract:
Nanogen, Inc. (Nasdaq: NGEN), developer of advanced diagnostic products announced today it has expanded its molecular reagent product portfolio to include real-time probes and primers designed to detect the presence of Epstein-Barr virus (EBV). EBV is the causative agent of infectious mononucleosis and also underlies several other lymphoproliferative disorders such as Burkitt's lymphoma.
Source:
Nanogen
Bookmark:
| Related News Press |
Nanomedicine
Tattoo therapy could ease chronic disease: Rice-made nanoparticles tested at Baylor College of Medicine may help control autoimmune diseases September 23rd, 2016
BBI Solutions launches innovative conjugate blocking technology that enhances signal intensity for lateral flow immunoassays September 20th, 2016
Iran to hold intl. school on application of nanomaterials in medicine September 20th, 2016
Graphene nanoribbons show promise for healing spinal injuries: Rice University scientists develop Texas-PEG to help knit severed, damaged spinal cords September 19th, 2016
Announcements
Chains of nanogold – forged with atomic precision September 23rd, 2016
Tattoo therapy could ease chronic disease: Rice-made nanoparticles tested at Baylor College of Medicine may help control autoimmune diseases September 23rd, 2016
Nanotech Grants Options September 22nd, 2016
Coffee-infused foam removes lead from contaminated water September 21st, 2016
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
University Technology Transfer & Patents
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||
